Cheung Cherry X, Healy Donagh A, Walsh Stewart R
1 Department of Surgery, University Hospital Waterford, Waterford, Ireland ; 2 Department of Surgery, National University of Ireland Galway, University Road, Galway, Ireland.
J Thorac Dis. 2016 Mar;8(3):E197-9. doi: 10.21037/jtd.2016.01.81.
Remote ischaemic preconditioning (RIPC) is an attractive cardioprotective strategy. Although results from animal studies and phase II study on humans are convincing, it cannot have a role in clinical practice until benefits in clinical outcomes are proven in phase III study. Two phase III studies were recently published [Remote Ischemic Preconditioning for Heart Surgery (RIPHeart) and Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery (ERICCA)] and this article discusses their design, results and implications.
远程缺血预处理(RIPC)是一种颇具吸引力的心脏保护策略。尽管动物研究和人体II期研究的结果令人信服,但在III期研究证明其对临床结局有益之前,它无法在临床实践中发挥作用。最近发表了两项III期研究[心脏手术的远程缺血预处理(RIPHeart)和远程缺血预处理对冠状动脉搭桥手术患者临床结局的影响(ERICCA)],本文将讨论它们的设计、结果及意义。